Growth factor receptors for T lymphocytes, such as interleukin 2 and insulin, are present on activated but not resting T lymphocytes. We sought to determine if insulin-like growth factor I (IGF-I) could act as a growth factor for human T cells and to characterize its receptor on resting and activated cells. Recombinant IGF-I induced two separate functions. It was chemotactic for and increased incorporation of tritiated thymidine into both unactivated (resting) and mitogen-activated T cells.
Introduction
Insulin-like growth factor I (IGF-I)1 is a polypeptide with insulin-like chemical structure and biologic properties (1) . It circulates as a high molecular weight complex bound to a specific carrier protein. IGF -I has been shown to be identical to somatomedin C and appears to be synthesized in many mammalian tissues (2) (3) (4) (5) (6) . Receptors for IGF-I have been identified in numerous tissues including placenta (7), fibroblasts (8) , neuronal tissue (9) , skeletal muscle (10) , Leydig cells (1 1), mononuclear cells (12) , and B lymphocytes (13) . In vivo, IGF-I is considered to be primarily a growth hormone-dependent circulating growth factor with an important effect upon skeletal growth (1) , while in high doses, IGF-I may function to regulate acute metabolic responses ( 14) . Accumulation ofrecirculating T lymphocytes at tissue sites is thought to occur by recruitment and subsequent local proliferation. The major means by which recruitment may occur is directed migration or chemotaxis (15) . In fact, several growth factors have been shown to be chemotactic for human T cells, including interleukin 1 (IL-1) (16, 17) , interleukin 2 (IL-2) (18) , antigen (19) , and insulin (20) , suggesting that such growth factors might be capable ofboth steps in the accumulation ofT lymphocytes: chemotaxis, and subsequent proliferation.
Insulin receptors are found on activated but not unactivated (resting) T cells (21) (22) (23) . Recently, we found insulin to be chemotactic for mitogen-activated human T lymphocytes in doses consistent with action on high-affinity insulin receptors (20) . This effect was not seen with resting T cells unless very high doses of insulin were used, consistent with the hypothesis that insulin was acting via lower-affinity IGF-I receptors. It has been demonstrated that insulin may compete to occupy IGF-I receptors (13, 24) . Because of the similarities between insulin and IGF-I and their receptors, we evaluated the chemotactic and proliferative responses of T lymphocytes to IGF-I. We determined IGF-I to be chemotactic for resting and activated T cells in doses consistent with action on highaffinity IGF-I receptors. IGF-I stimulated increased tritiated thymidine ([3H]T) incorporation into resting and activated T cells in a standard proliferation assay. We also characterized the IGF-I receptor on both resting and activated T cells employing binding assays and affinity cross-linking studies.
Methods
Isolation and purification of T lymphocytes. Human peripheral blood mononuclear cells (PBMC) were isolated from the heparinized venous blood of healthy human volunteers by density centrifugation on Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, NJ). Cells were recovered from the Ficoll-medium interface, washed three times in medium 199 (Ml99, Microbiological Associates, Bethesda, MD), supplemented with 100 U/ml penicillin and 100 ;tg/ml of streptomycin and 25 mM Hepes buffer (M199-HPS). Blood monocytes were removed by suspending 75 X 106 PBMC in 15 ml M199-HPS in sterile glass petri dishes for 1-2 h at 37°C. After incubation, the plates were washed five times with warmed (370C) media and the monocyte-depleted supernatant recovered. Nylon wool-nonadherent human T cell-enriched populations were prepared by a modification of the method of Julius et al. (25) . 3 Except for the absence ofIGF-I the control wells were identical in every way. Gradient dependence was determined by the checkerboard technique; IGF-I was placed below the filter only (chemoattractant present with concentration gradient) as well as both above and below (chemoattractant present without concentration gradient). Increased motility over baseline in the former setting represents a chemotactic (gradient-dependent) effect, and in the latter setting a chemokinetic (gradient-independent) effect (27) . Migration experiments were carried out for 3 h at 37°C in a 5% CO2 atmosphere. The filters were fixed, stained, dehydrated, and mounted by using standard histologic methods. Lymphocyte movement was quantitated by counting the total number of cells migrating beyond a fixed distance into the filter. Five highpower fields (hpf) were counted for each of the duplicate wells. Results were calculated as mean cells per high-power field±SD. Data were also expressed as mean percentage ofcontrol migration. Student's t test was utilized to determine the statistical significance of migration compared with control conditions. A P value of < 0.05 was considered significant in all chemotaxis experiments.
[3H]T incorporation assay. Phytohemagglutinin (PHA, 2 ug/ml; PHA-L, Sigma Chemical Co., St. Louis, MO), interleukin 2 (IL-2, 100 U/ml) (AmGen Biologicals), and IGF-I (I10-"' to 10-7 M) were added separately or in combination to human T Pilch and Czech (28, 29) . Intact human resting and PHA-activated T lymphocytes (25 X 106 cells) were incubated with 10-9 M '25I-IGF-I (106 cpm/assay), with or wkithout unlabeled IGF-I (10-' M), and incubated at room temperature for 30 min; unbound ligand was then removed by centrifugation at 500 g and discarding the supernatant. Disuccinimidyl suberate (DSS, Pierce Chemical Co., Rockford, IL) was added to yield a final concentration of0.5 mM. After 30 min the cells were exposed to 100 Ml of 1.5 M Tris (pH 8.7) while on ice for 15 min and then (total volume of 1 ml) were sonicated and centrifuged at 500 g for 10 min to remove nuclei. The supernatant was recovered and centrifuged (Eppendorf 5414 centrifuge) and the pellet was then suspended in 100 AL of phosphate-buffered saline, pH 7.4, plus 100 Ml of Laemmli sample buffer (0.5 M Tris-HCl, pH 6.7, 2% sodium dodecyl sulfate, 10% glycerol and 0.001% bromophenol blue); reduced samples contained dithiothreitol (100 mM). Samples were boiled for 2 min and then analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using a 3-10% gradient gel. Autoradiograms were developed for 48 h at -80°C, using Kodak X-Omat film (Eastman Kodak Co., Rochester, NY). The molecular weight standards used were myosin (200,000), ,-galactosidase (1 16 (Fig. 2) .
A checkerboard analysis was performed to determine ifthe effect of IGF-I upon motility was gradient dependent (chemo- Fig. 4 and for resting cells in Fig. 5 . A representative competition assay comparing IGF-I binding to that of insulin is tactic) or independent of the effect of a gradient (chemokinetic) (Fig. 3) . The response ofT cells to IGF-I was clearly greater when IGF-I was present below the filter only (i.e., gradient present). A significant chemokinetic effect was seen as well, in that cells showed significantly increased motility even when IGF-I was present in equal concentrations above and below the filter.
[3H]T incorporation. Migration is clearly enhanced in the presence of a~concentration gra4-dient, peaking at 228±15% with 10-9 M IGF-I; in the absence of a gradient migration peaked at 159±26%. *Significantly different from control conditions, P < 0.01. Affinity cross-linking. Utilizing DSS, '25I-IGF-I was effectively cross-linked to 48-h PHA-activated as well as to resting T cells (Fig. 6) . Under nonreducing conditions, the major labeled species was a 360,000-mol wt moiety compatible in size with the IGF-I receptor (32) . Polypeptides corresponding to 270,000 and 135,000 mol wt (after subtraction of the 7,500 mol wt contributed by the cross-linked 125I-IGF-I) were identified under reducing conditions. Excess unlabeled IGF-I effectively prevented the cross-linking of radiolabeled ligand in each case. Although the 270,000-mol wt band corresponds roughly in size with the insulin-like growth factor II (IGF-II) receptor under reducing conditions, there was no band compatible with the IGF-II receptor under nonreducing conditions. We therefore believe that the 270,000 mol wt species most likely represents a chain-a chain cross-linking, as previously described (33) . The 135,000-mol wt band corresponds in size to the a chain of the IGF-I receptor. We obtained labeling of a band of identical size by cross-linking 1251I-IGF-I to HuT 78 cells (data not shown).
Discussion
We investigated the effect of recombinant human IGF-I on cellular growth and motility of purified human blood T lymphocytes. We found IGF-I to be chemotactic and chemokinetic for both resting and activated human T lymphocytes. Chemotactic responsiveness was identical in CD4' and CD8' cells. IGF-I also stimulated increased uptake of [3H]T into T lymphocytes cultured in a defined medium containing no growth factors such as insulin. This effect was demonstrated in both resting and PHA-activated T cells. The lack of increased thymidine incorporation seen in resting cells treated with IL-2 (100 U/ml) suggests that these cells were indeed in a resting state, and that entry of cells into the cell cycle was induced by IGF-I alone. The effect of IGF-I on PHA-activated cells was equivalent to that seen with IL-2. Flow cytometric analysis was utilized to confirm the effects of IGF-I on [3H]T incorporation. Dose response analysis suggested that IGF-I induced cellular motility and entry into the cell cycle at doses consistent with action on a high affinity IGF-I receptor. We then investigated whether the effects of IGF-I on purified T cells might be mediated by the receptor for IGF-I. We have shown that IGF-I binds specifically to both resting and activated T lymphocytes. Scatchard analysis for IGF-I binding revealed a Kd similar to that found in other tissues (1.2 X 10-10 M). Finally, we have demonstrated the presence of the receptor on the surfaces of both resting and activated purified T cells and on a malignant T cell line by affinity cross-linking.
The molecular mechanisms of leukocyte chemotaxis are complex and are reviewed elsewhere (34) . Cell locomotion is dependent upon complex cytoskeletal changes. IGF-I has been shown to effect reorganization of the cytoskeleton in a human squamous cell line (35) , suggesting that it might be a growth factor capable of inducing cell motility. The effect of IGF-I upon lymphocyte motility has not been previously demonstrated, although other growth factors including IL-I (16, 17), IL-2 (18) , and insulin (20) have recently been shown to be chemotactic for either activated (IL-2) or both resting and activated (IL-1, insulin) T cells. We believe that the effect of IGF-I upon cell motility is receptor-mediated. It is possible that a nonspecific growth factor effect not mediated through receptor binding is responsible for the results we obtained. We have demonstrated that IGF-I is chemotactic for resting and activated human T lymphocytes with a half-maximal concentration consistent with the Kd of the receptor, providing evidence that the effect shown is mediated via high-affinity IGF-I receptors. In addition, the gradient-enhanced motility (chemotaxis) and high-dose inhibition demonstrated resemble that seen with insulin (20) , , and with other receptor-mediated chemotaxis models such as N-formylated-methionyl peptides for neutrophils (36, 37) and platelet-derived growth factor for neutrophils and monocytes (38, 39) . However, the precise mechanism through which IGF-I enhances T cell motility is unclear.
Insulin receptors are not present on resting T cells, but are inducible by mitogen activation (21) (22) (23) 40 (13, 24) and it has been proposed that the major mitogenic actions of insulin result from its binding to the IGF-I receptor rather than to the insulin receptor itself (41) . IGF-I is chemotactic for both CD4' and CD81 T cells, similar to the identical response of these subsets to insulin (20) . This is in contradistinction to IL-2, which is chemotactic only for CD4' T cells (18) .
Mitogenic effects of IGF-I have been demonstrated upon IM-9 lymphocytes, a lymphocytoblastoid B cell line (42) (Table I) . A recent study (43) Evidence for presence of the IGF-I receptor on resting T cells by competitive binding and affinity cross-linking provides a basis for its behavior as a competence factor. These data suggest that IGF-I produced locally in tissues such as thymus (6) or inflammatory sites might affect the growth and function of IGF-I receptor-bearing T lymphocytes. IGF-I is vital to normal growth. A defect in IGF-I secretion during puberty prohibits growth acceleration; this defect is exemplified in African pygmies (45) . Low IGF-I levels also occur in Laron dwarfism (46) and in malnutrition (47, 48) . However, the extent of the biologic importance of IGF-I may not yet be realized. In situ hybridization histochemistry studies suggest ubiquitous IGF synthesis with fibroblasts and mesenchymal cells within connective tissues as predominant sites (6) . The IGF-I receptor is found in numerous tissues as well and the mitogenic actions of IGF-I upon multiple tissues (1, 3) support a more extensive role for this ligand-receptor system. In addition, fibroblasts both synthesize IGF-I (4, 49, 50) and bear IGF-I receptors on their surfaces (51, 52) ; the cellular production of "somatomedin-like peptides" has been suggested as an example of the autocrine model of growth regulation (53) . Because T lymphocytes are frequently involved with fibrotic tissue reactions the link between the chemotactic and growth factor activity ofIGF-I may be important in the recruitment to and activation of effector lymphocytes at sites of fibroblast activation.
The chemotactic and mitogenic phenomena, which we have determined, prompted us to pursue more definitive proof of the IGF-I receptor on the surface of T cells. We demonstrated competitive binding of IGF-I on the surfaces of both resting and activated T cells and analyzed the results by the method of Scatchard (31) . The resultant curvilinear plot could be interpreted as representative of a heterogenous population of receptors, i.e., high and low affinity receptors. Other possibilities such as negative cooperativity (54) or tighter binding of labeled IGF-I than of the unlabeled ligand (55) might be considered. Both linear (9, 56) and curvilinear (57, 58) plots have been reported with IGF-I binding in other human tissue types. Our results demonstrate that IGF-I binds specifically to the surface of T lymphocytes. In addition, a cold competition assay was performed comparing the relative abilities of unlabeled insulin and IGF-I to displace '25I-IGF-I from resting T cells; insulin binding was demonstrated only with very high doses of insulin. We believe that this provides a compelling argument for IGF-I binding to resting T cells. It is difficult to be absolutely certain that our results represent a small amount of high-affinity IGF-I receptors on all of the cells; possibly a small subpopulation of cells has a larger number of receptors. Use of the fluorescent activated cell sorter enabled us to be certain that the cells were at least 95% CD3+. The concentration of '251I-IGF-I used in our cross-linking assays was low enough to exclude the possibility of IGF-I binding to insulin receptors which are present on activated T cells. Affinity cross-linking has been utilized in characterizing the quaternary structure of protein oligomers (59, 60) including the insulin (28, 29) and IGF-I (26, 61) receptors. We found the size of the IGF-I receptor complex and its binding subunit to be compatible with that found in other tissues (26, (62) (63) (64) .
We conclude that IGF-I is chemotactic and mitogenic for both resting and activated human T cells in vitro. The IGF-I receptor that we have demonstrated to be present on the surface of T cells likely mediates these phenomena.
